Koshinski Asset Management Inc. raised its position in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 2.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,528 shares of the medical research company’s stock after acquiring an additional 165 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Edwards Lifesciences were worth $623,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. Trifecta Capital Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $28,000. Addison Advisors LLC raised its stake in Edwards Lifesciences by 708.0% during the 4th quarter. Addison Advisors LLC now owns 404 shares of the medical research company’s stock worth $30,000 after buying an additional 354 shares during the period. Compass Wealth Management LLC bought a new position in Edwards Lifesciences in the fourth quarter worth approximately $31,000. New England Capital Financial Advisors LLC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $42,000. Finally, CoreCap Advisors LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $44,000. Institutional investors and hedge funds own 79.78% of the company’s stock.
Analyst Upgrades and Downgrades
EW has been the subject of several research reports. Citigroup lifted their price target on shares of Edwards Lifesciences from $92.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, April 3rd. StockNews.com initiated coverage on shares of Edwards Lifesciences in a research report on Thursday, May 18th. They set a “buy” rating for the company. Piper Sandler lifted their price target on Edwards Lifesciences from $80.00 to $83.00 in a research note on Thursday, April 27th. Mizuho increased their price objective on Edwards Lifesciences from $85.00 to $95.00 in a research note on Tuesday, April 25th. Finally, UBS Group initiated coverage on Edwards Lifesciences in a research report on Tuesday, March 28th. They set a “neutral” rating and a $84.00 target price on the stock. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $90.00.
Edwards Lifesciences Price Performance
Edwards Lifesciences (NYSE:EW – Get Rating) last issued its earnings results on Wednesday, April 26th. The medical research company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.39 billion. Edwards Lifesciences had a net margin of 27.07% and a return on equity of 25.81%. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.60 EPS. Equities analysts expect that Edwards Lifesciences Co. will post 2.55 EPS for the current year.
Insiders Place Their Bets
In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the company’s stock in a transaction dated Thursday, April 6th. The stock was sold at an average price of $83.09, for a total transaction of $558,780.25. Following the sale, the vice president now directly owns 62,824 shares in the company, valued at $5,220,046.16. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Michael A. Mussallem sold 19,875 shares of the business’s stock in a transaction dated Friday, April 14th. The stock was sold at an average price of $84.20, for a total transaction of $1,673,475.00. Following the completion of the transaction, the chief executive officer now directly owns 60,948 shares in the company, valued at $5,131,821.60. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 6,725 shares of the firm’s stock in a transaction dated Thursday, April 6th. The shares were sold at an average price of $83.09, for a total value of $558,780.25. Following the completion of the sale, the vice president now directly owns 62,824 shares in the company, valued at approximately $5,220,046.16. The disclosure for this sale can be found here. Insiders sold a total of 201,151 shares of company stock worth $17,523,816 in the last quarter. 1.29% of the stock is owned by company insiders.
Edwards Lifesciences Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.
Featured Stories
- Get a free research report on Edwards Lifesciences from StockNews.com
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Wayfair: From Steep Decline to Recent Surge
- Five stocks we like better than Edwards Lifesciences
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Get Rating).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
